Clinical presentation,treatment and outcome in 31 dogs with presumed primary colorectal lymphoma (2001–2013) |
| |
| Authors: | I. Desmas J. H. Burton G. Post O. Kristal M. Gauthier J. F. Borrego A. Di Bella A. Lara‐Garcia |
| |
| Affiliation: | 1. Royal veterinary College, Hatfield, UK;2. Flint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA;3. The Veterinary Cancer Center, Norwalk, CT, USA;4. Chavat Daat Veterinary Speciality Center, Beit Berl, Israel;5. Mississauga Oakville Veterinary Emergency Hospital and Referral Services, Oakville, ON, Canada;6. School of Veterinary Medicine, University of Madison‐Wisconsin, Madison, WI, USA;7. Vets Now Referrals, Medicine Service, Glasgow, UK |
| |
| Abstract: | The objective of this multicentre retrospective study was to describe clinical presentation, treatment and outcome and to determine prognostic factors for dogs with presumed primary colorectal lymphoma (PCRL). A total of 31 dogs were included. The predominant features of PCRL were high grade (n = 18) and immunophenotype B (n = 24). Most dogs were substage b (n = 25) with higher prevalence of haematochezia (n = 20). One dog had surgery only. Thirty dogs received chemotherapy; amongst them 13 had surgery or radiotherapy. Progression free survival (PFS) was 1318 days and disease‐related median survival time (MST) was 1845 days. Fourteen dogs were alive at the end of the study with a median follow‐up time of 684 days (3–4678 days). Younger dogs had longer PFS (P = 0.031) and disease‐related MST (P = 0.01). Presence of haematochezia corresponded with longer PFS (P = 0.02). Addition of local treatment to chemotherapy did not significantly improve the outcome (P = 0.584). Canine PCRL has considerably longer PFS and MST than other forms of non‐Hodgkin's lymphoma. |
| |
| Keywords: | canine chemotherapy colorectal lymphoma |
|
|
